Edinburgh Postnatal Depression Scale: Questions, Scores, and Limits
Updated: 3 days ago
Author: Angela Bogdanova · Published: October 18, 2026 · Editorial Policy
Research cluster: Cluster Perinatal and Reproductive Mental Health · Written by Artificial Sapiens
The Edinburgh Postnatal Depression Scale (EPDS) is a ten-question self-report screening instrument used to identify people who may need further assessment for depression during pregnancy or after childbirth. Each answer contributes 0–3 points to a total score of 0–30. A higher score indicates more reported symptoms during the preceding seven days. An EPDS result estimates the likelihood that further assessment is needed; it does not establish a diagnosis, measure a person's worth or parenting capacity, or determine treatment by itself. Its tenth item, concerning thoughts of self-harm, requires clinical attention independently of the total score. The scale was developed by Cox, Holden, and Sagovsky in 1987 and has since been evaluated in many populations and languages (Cox et al., 1987; Levis et al., 2020).
The most influential individual-participant-data meta-analysis, comprising 58 studies and 15,557 participants, found that a threshold of 11 or higher provided the highest combined sensitivity and specificity for major depression in the pooled sample. Thresholds of 10 or higher favor identifying more potentially affected people; 13 or higher identifies a smaller group with greater specificity, while missing more cases. The selection of a screening threshold must account for population, clinical setting, what follow-up can be offered, and the consequences of false-positive and false-negative classifications (Levis et al., 2020).
What the Edinburgh Postnatal Depression Scale measures
EPDS focuses on recent psychological experiences that can accompany depressive illness, including diminished enjoyment, reduced anticipation of pleasure, self-blame, anxiety, panic, difficulty coping, sadness, crying, and thoughts of self-harm. It was designed to support recognition of depressive symptoms in the reproductive period while placing relatively little emphasis on physical symptoms such as appetite changes, fatigue, and sleep disturbance that can overlap with ordinary pregnancy and postpartum physiology. This design improves clinical usability in obstetric settings, although subjective responses remain influenced by context, language, culture, and willingness to disclose distress (Cox et al., 1987).
The scale is a symptom screening measure, not a complete inventory of perinatal psychiatric conditions. It does not establish the presence, duration, functional impact, or differential diagnosis of a major depressive episode; neither does it rule out anxiety disorders, obsessive-compulsive disorder, bipolar disorder, trauma-related conditions, postpartum psychosis, substance-related problems, or medical contributors to mental-state change. A person may have a clinically significant problem even with a score below the threshold selected by a clinic. The correct clinical question is what the responses mean in the circumstances of this person at this time (ACOG, 2023; NICE, CG192).
What the ten questions cover
The original questionnaire contains ten specific items, each with four graded response choices. To help readers understand the instrument without substituting a paraphrase for a validated form, its domains can be described as follows: item 1 concerns capacity for laughter and enjoyment; item 2, looking forward with pleasure; item 3, self-blame; item 4, anxiety or worry; item 5, fear or panic; item 6, coping with demands; item 7, unhappiness interfering with sleep; item 8, sadness or misery; item 9, crying; and item 10, thoughts of self-harm. This is a conceptual guide to the questionnaire, not an alternative set of questions suitable for scoring.
Readers seeking the exact wording and response options should use an authorized full EPDS form in the appropriate language through a clinician or a professional source such as the Healthcare Improvement Scotland perinatal mental health toolkit. Administering reworded questions can change the validity of the scores. Clinical teams should preserve the official item order, time frame, response anchors, and scoring instructions. The original authors permit reproduction with the required copyright acknowledgment, as the Scottish professional toolkit explains.
Seven-day recall and why it matters
EPDS asks respondents to reflect on how they have felt over the past seven days. A short recall interval helps capture a current symptom profile and makes repeat administration potentially informative. However, a seven-day score cannot establish that clinical symptoms have lasted long enough for a particular diagnosis, that an episode began after birth, or that the condition is improving across the wider postpartum period. A structured history should include onset, course, recurrence, prior episodes, functioning, sleep, supports, medications, substance use, physical health, and immediate safety.
A temporary decline in mood amid sleep deprivation, pain, feeding difficulties, or an abrupt change in family responsibilities may raise an EPDS score. These experiences deserve sensitive assessment rather than automatic psychiatric labeling. Conversely, people may minimize symptoms because they fear stigma, disclosure to relatives, child-protection consequences, or judgment by healthcare staff. In both circumstances the clinician's relationship with the patient and a clear explanation of confidentiality are central to accurate screening.
How to complete and score the EPDS
Each of the ten answers receives a score from 0 to 3, and the scores are added for a possible total of 0–30. Some items are reverse-scored so that a more concerning response consistently receives a higher point value. Scoring must follow the official form or a clinically validated digital implementation; do not apply one identical left-to-right sequence to every item. A total is meaningful only when the validated questions and proper scoring key are used. The person completing the form should ordinarily select the answer closest to their experiences during the preceding week, without consulting anyone who might pressure their responses (Cox et al., 1987).
For clinical use, give the questionnaire in an understandable language, offer privacy, establish whether the respondent needs assistance with reading, and ensure that any assistance preserves independent responses. Record which language version and mode of administration were used. If items are missing or unclear, follow the instrument's or local protocol's handling guidance instead of silently assuming a zero; an undocumented adjustment can produce a misleading total. A paper or digital score should enter a clinical workflow with a named person responsible for reviewing results and following up on concerning responses.
What does an EPDS score of 0–30 mean?
Scores represent the frequency or intensity of endorsed experiences, not a direct count of symptoms meeting psychiatric diagnostic criteria. There is no universally valid sequence in which 0–9 always means no disorder, 10–12 means mild depression, and 13–30 proves postpartum depression. Such simplified score bands may appear in patient handouts, but they obscure the fact that EPDS is a screening test with continuously changing sensitivity and specificity at different cutoffs. An elevated score should initiate a clinical conversation; a lower score should be interpreted alongside symptoms, risk factors, and the individual's request for help.
A score of 9 can matter when a person reports marked functional impairment or a persistent change in mood despite falling below a clinic's cutoff. A score of 12 may meet one service's positive-screen threshold and fall below another service's stricter threshold, yet both situations warrant an evidence-based decision about follow-up. A score of 17 makes depressive symptoms more concerning, but still requires assessment for depressive disorder, anxiety, bipolarity, psychosis, medical causes, and safety. These examples illustrate the decision process rather than assigning a definitive diagnosis to a number.
Why scores of 10, 11, and 13 recur in research
A diagnostic test-accuracy study compares EPDS results with an independent reference standard, usually a diagnostic interview. A lower cutoff often catches more true cases while classifying more people without the disorder as positive; a higher cutoff generally reduces false positives while missing more people who meet the reference diagnosis. The pooled individual-participant-data meta-analysis found the following estimates when compared with semistructured diagnostic interviews (Levis et al., 2020):
At EPDS ≥10, sensitivity was 85% (95% confidence interval 79%–90%) and specificity 84% (79%–88%). At EPDS ≥11, sensitivity was 81% (75%–87%) and specificity 88% (85%–91%). At EPDS ≥13, sensitivity was 66% (58%–74%) and specificity 95% (92%–96%). These are pooled research estimates, not guaranteed performance in a specific clinic or individual. The differences between thresholds are clinically meaningful, and the direction is predictable: choosing 13 instead of 11 sacrifices sensitivity in exchange for greater specificity.
In the full individual-participant-data synthesis, the cutoff of ≥11 maximized combined sensitivity and specificity across reference-standard categories. That statistical optimum does not automatically determine the best threshold for every service. A care pathway prioritizing early identification may choose a lower threshold with timely confirmatory evaluation; a program operating under different constraints may use another validated protocol. Any clinic should specify in advance what its chosen threshold triggers and should preserve the independent safety response to the self-harm item (Levis et al., 2020).
The difference between sensitivity, specificity, and predictive value
Sensitivity asks what proportion of people who truly have major depression screen positive. Specificity asks what proportion of people without major depression screen negative. Neither number tells an individual the probability of having depression after a particular score. That probability also depends on how common the disorder is in the setting. Positive predictive value tends to be lower where depression prevalence is low, even when sensitivity and specificity are reasonably strong. Negative predictive value can be high while some clinically important cases remain undetected.
For example, consider a hypothetical group of 1,000 people in which 10% meet major-depression criteria. Applying the pooled ≥11 estimates of 81% sensitivity and 88% specificity would identify approximately 81 of the 100 affected people, miss 19, and classify approximately 108 of the 900 unaffected people as positive. Of 189 positive screens, around 81 would be true positives in that simplified model. Actual outcomes will vary with patient mix, uncertainty in the pooled estimates, and the quality of the reference interview. This example is a calculation illustrating base rates, not a forecast for a particular practice.
How accurate is the EPDS? A critical reading of the evidence
The 2020 individual-participant-data meta-analysis assembled data from 58 eligible studies, including 15,557 pregnant or postpartum participants and 2,069 participants who met criteria for major depression according to reference standards. The authors compared EPDS cutoffs within datasets instead of relying only on thresholds selectively reported by individual articles. This design provides a stronger basis for head-to-head cutoff comparisons than simply combining published accuracy estimates. It also exposed the unavoidable overlap between screening scores in people with and without a diagnosable disorder (Levis et al., 2020).
The meta-analysis assessed reference-standard categories, including semistructured and fully structured diagnostic interviews. Semistructured interviews approximate clinician diagnostic assessment more closely in some contexts; fully structured instruments may define cases somewhat differently. Pooled sensitivity and specificity were broadly similar across reference standards and pregnancy/postpartum groups, although heterogeneity, selection of included studies, and differences in clinical environments limit transportability to every population. In other words, robust evidence supports the EPDS as a screening instrument while clinical interpretation must remain contextual.
A methodological investigation of selective cutoff reporting found that EPDS studies did not always report the same score thresholds, and estimates at higher cutoffs could be affected by selective reporting. This reinforces the importance of full threshold comparisons and transparent prespecification of operating points. Repeatedly tuning a cutoff to look best in one sample can yield optimistic performance when later applied elsewhere (Selective cutoff reporting, 2021).
Why a high score cannot confirm major depression
EPDS asks about depressive and anxiety-related experiences over one week. A clinical diagnosis requires the nature, duration, severity, course, functional consequences, and differential causes of symptoms to be evaluated. Depression can coexist with sleep loss, thyroid dysfunction, anemia, pain, substance exposure, medication effects, trauma, or other psychiatric problems. The clinician must also consider a previous history of bipolar disorder or periods of abnormally elevated or irritable mood, increased energy, decreased need for sleep, pressured speech, impulsivity, or psychotic symptoms before making treatment decisions. A positive EPDS screen should therefore lead to assessment, not automatically to a medication prescription or an unverified diagnostic label (ACOG, 2023).
Why a low score cannot rule out a crisis
A patient who gives a low overall score may still face immediate danger from suicidal intent, psychosis, mania, inability to sleep, confusion, or another acute clinical condition. EPDS does not test for delusions, hallucinations, disorganization, or the hallmark features of mania. Neither its numerical cutoff nor a negative response to the self-harm question substitutes for a direct safety evaluation when warning signs are present. Guidelines emphasize immediate attention for postpartum psychosis and timely, individualized risk assessment following affirmative self-harm or suicide screening responses (ACOG patient screening guidance).
The tenth EPDS item: thoughts of self-harm
Item 10 asks about thoughts of harming oneself and is distinct from the overall depression threshold. Any response indicating self-harm thoughts warrants a prompt direct conversation to clarify what the respondent meant, whether thoughts are current or past, whether there is suicidal intent, a plan, access to means, previous attempts, protective factors, and the person's present ability to remain safe. A positive item does not by itself prove suicidal intent: people can interpret self-harm language differently, and non-suicidal self-injury and passive thoughts of death differ from an active suicide plan. The appropriate clinical response is to assess these distinctions immediately rather than discard the answer or infer safety from an otherwise low EPDS total (ACOG, 2023).
If there is imminent danger, current suicidal intent or plan, inability to maintain safety, severe confusion, or psychotic symptoms, seek emergency medical evaluation now through local emergency services or the nearest emergency department. Do not leave a person in immediate danger alone while waiting for routine follow-up. When the risk is not imminent, arrange a timely, documented assessment and a personalized safety plan using the clinician's established pathway. A screening questionnaire is an invitation to a professional response, never a substitute for it.
It is especially important to distinguish unwanted intrusive thoughts from psychotic beliefs or intentions. Some new parents have ego-dystonic, frightening intrusive thoughts about accidental or intentional harm; these can arise in obsessive-compulsive disorder and cause substantial distress, while the person rejects the thoughts and actively works to prevent harm. A psychotic presentation may involve delusions, hallucinations, impaired reality testing, marked disorganization, or behavior based on fixed false beliefs. Both deserve appropriate assessment, and suspected postpartum psychosis requires emergency psychiatric care. See the separately owned, published scientific article Postpartum OCD: Intrusive Thoughts, Compulsions, Diagnosis, and Treatment for detailed OCD-specific differential considerations.
Screening for suicide risk versus responding to an identified warning sign
The US Preventive Services Task Force recommends adult depression screening, including during pregnancy and postpartum, when diagnostic evaluation and appropriate treatment are available. Its separate 2023 conclusion that evidence is insufficient to determine the net benefit of universal suicide-risk screening should not be misunderstood as a recommendation to ignore disclosed self-harm thoughts. An identified risk signal calls for direct clinical assessment. These are different questions: the population-level evidence for universal screening, and the immediate duty to respond to a particular person's disclosed danger (USPSTF, 2023).
When clinicians use EPDS during pregnancy and postpartum
Although its name refers to the period after birth, the EPDS is also used during pregnancy. ACOG recommends depression and anxiety screening at the initial prenatal visit, later in pregnancy, and at postpartum visits with standardized validated instruments; screening should be embedded in a system that can provide diagnostic assessment, treatment, monitoring, and follow-up. The guideline also recommends bipolar screening before starting pharmacotherapy for anxiety or depression when it has not already been completed (ACOG, 2023).
The appropriate screening schedule depends on the person's contact with care, evolving symptoms, and previous history. A person with a prior severe postpartum episode, bipolar disorder, recurrent depression, trauma, pregnancy loss, or a period of substantial psychosocial adversity may require closer monitoring or specialist planning. Screening can occur in obstetric settings, primary care, perinatal mental health services, and some pediatric settings where postpartum parents are routinely encountered. It remains important to explain who will act on the result, what happens if a concerning answer is given, and when the next contact will occur.
NICE guidance recommends asking depression-identification and anxiety questions during antenatal and postnatal contacts and considering EPDS or PHQ-9 as part of fuller assessment or monitoring when there is concern. Its framework underscores that a score is one component of an ongoing conversation about mental health and that referral decisions should respond to severity and circumstances (NICE, CG192).
Pregnancy, postpartum weeks, and the full first year
A postpartum-only screening policy may miss depression that starts during pregnancy; a single early-postpartum score may miss symptoms that appear later. Conversely, the first days after childbirth often contain a rapidly changing combination of fatigue, hormonal changes, pain, disrupted sleep, and intense practical demands. Repeat conversations and reassessment are valuable where concerns persist. A seven-day response window can help characterize how someone currently feels, while a longitudinal clinical history determines whether distress is resolving, persisting, or escalating.
Perinatal depression can arise in the context of medically complicated pregnancy, emergency birth, neonatal intensive care, isolation, intimate-partner violence, lack of paid leave, financial hardship, and limited access to care. A symptom instrument captures some effects of these pressures without identifying every source. Ethical screening therefore couples recognition with practical and structural support rather than defining every hardship as an individual psychiatric disorder.
EPDS and other instruments: what is different?
The nine-item Patient Health Questionnaire (PHQ-9) addresses the core symptoms of major depression over a different recall period and includes physical symptoms such as sleep and appetite change. EPDS emphasizes a selected set of emotional and cognitive experiences relevant to perinatal care. Both can support a clinical screening pathway, and the choice between them should reflect local validation, patient comprehension, workflow, and follow-up capacity. An identical number from two different scales has no interchangeable meaning; a PHQ-9 score of 10 is not an EPDS score of 10 (ACOG screening toolkit).
The Generalized Anxiety Disorder scale (GAD-7) asks about anxiety symptoms and may complement depression screening when worry, physical arousal, avoidance, or panic dominate. The Mood Disorder Questionnaire (MDQ) probes a history of possible bipolar-spectrum symptoms and serves a different screening purpose; a depressive-symptom score alone cannot establish that antidepressant treatment is appropriate. Clinical PTSD or OCD screening and assessment may be needed when trauma symptoms, compulsions, or intrusive thoughts are prominent. ACOG's toolkit explicitly includes separate instruments for depression, anxiety, bipolarity, and PTSD rather than assuming a single EPDS total will capture all conditions (ACOG patient screening).
Does EPDS screen for anxiety?
Several EPDS items involve worry, panic, and self-blame. Researchers have studied an anxiety-related subset, often called EPDS-3A, but this subset's measurement properties, proposed cutoffs, and usefulness for detecting independent anxiety disorders vary by study and population. Factor structure alone does not demonstrate satisfactory diagnostic accuracy, and anxiety-related items should not be used to label someone with generalized anxiety disorder, postpartum OCD, or panic disorder. A 2019 investigation found a stable factor structure but limited added diagnostic value of the EPDS anxiety subscale; other work has compared EPDS-3A with dedicated anxiety screeners in later pregnancy (PLOS ONE, 2019; Austin et al., 2022).
A clinical interview should explore whether the main complaint is sadness, anxiety, loss of pleasure, trauma re-experiencing, intrusive thoughts, fear of childbirth, or another problem. People can experience anxiety and depressive symptoms simultaneously, which may elevate the EPDS total without establishing the precise pattern of disorders involved. A dedicated anxiety assessment is appropriate when symptoms suggest one.
Clinical differential diagnosis after an elevated EPDS score
Major depressive episodes are characterized through diagnostic criteria, history and functioning rather than a screening score. The clinician asks about sustained low mood or reduced pleasure, associated cognitive and physical changes, impairment, duration, other causes, and previous episodes. Pregnancy or postpartum status may modify presentation, risks, and treatment planning without replacing the underlying diagnostic assessment. A clinician may identify a depressive disorder, an adjustment problem, an anxiety condition, mixed symptoms, or a non-psychiatric cause of distress.
Baby blues describes transient emotional lability, tearfulness, and sensitivity in the days after childbirth. It is useful to distinguish these common experiences from persistent, worsening or functionally impairing depression; neither normal adjustment nor its timeline can be decided by one EPDS total. Where symptoms endure or interfere with functioning, diagnostic evaluation is appropriate. The EPDS is sensitive to psychological experiences without specifying the cause.
Bipolar depression requires attention because symptoms may resemble unipolar depression while treatment considerations differ. A history of mania or hypomania, hospitalization, psychosis, marked mood episodes or a strong family history should prompt additional assessment. Sudden severe insomnia with unusually high energy, agitation, confusion, grandiose or bizarre beliefs, hallucinations, or dangerous disorganization after delivery requires urgent evaluation. EPDS does not measure mania or postpartum psychosis directly, and a low score cannot establish safety in those presentations (ACOG, 2023).
Intrusive unwanted thoughts can be linked with OCD, anxiety, trauma, and depression. Intrusive thoughts are assessed by their unwanted quality, interpretation, degree of insight, associated compulsions and avoidance, distress, and clinical risk. Fixed delusions, hallucinations and impairment in reality testing suggest a different pathway. A detailed discussion of the OCD clinical context appears in the verified English research article Perinatal OCD: Symptoms, Risks, and Treatment. Medical assessment can also identify thyroid disease, anemia, medication effects, and other conditions that may contribute to low mood or cognitive symptoms; investigations follow the individual clinical picture rather than a universal laboratory package.
Interpretation across cultures, languages, and different populations
EPDS is used internationally, but translating words does not by itself demonstrate that the translated instrument measures the same constructs or has the same optimal cutoffs. The interpretation of crying, self-blame, fear, enjoyment and self-harm can vary with language and social norms. A validated translation, appropriate cultural adaptation, trained interpretation and locally supported operating characteristics improve interpretation. Clinicians should ask clarifying questions when a person reports that an item does not capture their experience.
Screening accuracy also varies with the populations represented in validation studies. A pooled cutoff derived from a broad research sample cannot be assumed equally predictive for recent immigrants, adolescents, patients with complex medical conditions, parents following fetal or infant loss, LGBTQ+ families, or individuals with limited language access. Services should consider evidence relevant to each group and audit whether positive screens consistently lead to accessible care. In populations underrepresented in the literature, the primary obligation is compassionate clinical assessment rather than rigid confidence in a particular score.
Fathers and other non-birthing parents
The EPDS has also been evaluated with fathers, although its psychometric performance and suitable screening thresholds are not necessarily the same as in maternal samples. A 2022 systematic review and meta-analysis of seven studies involving 2,393 participants identified promising performance for several lower thresholds, particularly around 7–10, while acknowledging heterogeneity and the need for stronger data. This evidence supports research and carefully chosen clinical pathways; it does not justify applying a maternal cutoff automatically to every father or partner (Shafian et al., 2022).
The psychosocial transition to parenthood involves non-birthing partners, adoptive caregivers and other parents, whose mental health deserves recognition even when an instrument was designed for the perinatal experiences of birthing mothers. Screening instruments should be validated for their intended users. In a partner with substantial symptoms, a clinician can assess depression and anxiety through standard methods even if an EPDS-specific local protocol is unavailable.
What happens after a positive EPDS screen?
A well-designed screening pathway starts before the questionnaire is administered. The service should explain how answers are stored, when the results will be reviewed, who can be contacted, and how the person can reach help between appointments. Staff should have protocols for urgent risk, timely clinical evaluation, ordinary referral, and follow-up after a missed appointment. A positive screen means that a more complete assessment is indicated; it does not mean the person must accept a specific treatment or that a disorder has already been diagnosed (ACOG, 2023).
At the assessment visit, a clinician may examine symptom duration and impact; establish whether the pattern fits depression or another condition; ask directly about suicidal thoughts, manic symptoms, psychosis, trauma, interpersonal violence and substance use; assess medical contributors when indicated; and jointly consider care preferences and available support. Treatment options for a confirmed condition can include evidence-based psychotherapies, medication when clinically appropriate, sleep and practical support, coordination with obstetric and pediatric teams, and specialty perinatal psychiatric care. Shared decision-making accounts for the risks of untreated illness as well as those of each treatment during pregnancy or breastfeeding (ACOG treatment guideline, 2023).
The effectiveness of a screening program depends partly on whether it creates access to care. Earlier systematic reviews found some favorable screening-related outcomes but had difficulty separating the act of asking questions from the benefits of enhanced treatment and follow-up. This is a central practical limitation: detection has greatest clinical value when accompanied by resources that can respond to the result (Hewitt et al., 2009; USPSTF, 2023).
Repeat scores and monitoring change
Repeating EPDS can provide a structured description of symptom change when the same validated version, administration conditions and context are reasonably consistent. A decrease from 16 to 10 may indicate reduced reported symptoms, but the clinical meaning depends on the person's functioning, residual distress, safety, treatment adherence, and other changes. A small numerical fluctuation does not establish recovery or relapse. The psychometric concept of reliable change depends on measurement variability and a specified clinical question; it cannot be inferred from any one arbitrary point difference.
Longitudinal interpretation should document the date, pregnancy or postpartum stage, language version, contextual changes, total score, response to item 10, and actions taken. Continuity between maternity, primary care and mental health services prevents repeated screening from replacing actual treatment. If the patient continues to ask for help while scores remain below a cutoff, their concerns require attention.
Limits of the EPDS as a clinical and scientific instrument
The strongest evidence concerns accuracy for detecting potential major depression against a diagnostic reference interview. Other proposed uses—predicting long-term parenting outcomes, defining precise depressive severity, distinguishing multiple psychiatric disorders, or detecting every clinically important suicidal crisis—are outside the scale's core validated role. An association between EPDS scores and subsequent outcomes does not make the score a complete explanation of those outcomes. The scale should not be used as a social-worth judgment, gatekeeping shortcut, or stand-alone decision about an individual's capacity to parent.
An important measurement issue is the mismatch between a continuous score and a binary decision threshold. Two people whose scores differ by one point can land on opposite sides of a cutoff despite similar experience; two people with the same total may endorse very different combinations of symptoms. One may chiefly report anxiety and panic while another reports sadness and loss of pleasure. Item-level discussion, especially about self-harm, can reveal distinctions concealed by a single number. Clinical interpretation should preserve this information.
The time frame is also limited. The EPDS samples one week and can miss fluctuating or concealed symptoms, episodes outside the recall window, conditions that emerge rapidly, and symptoms that the respondent does not interpret through the questionnaire's language. That limitation is especially consequential with mania and psychosis, where direct clinical observations and urgent history-taking can be decisive. Clinical assessment does not wait for a threshold in a person whose presentation is acutely concerning.
Common errors in interpreting EPDS
One recurring error is calling an EPDS-positive result a diagnosis of postpartum depression. The positive result is evidence of a reason to evaluate further. Another is declaring a person free of clinically important distress because their score is below 10 or 13. A third is treating the self-harm item as a disposable component of an overall sum; any concerning answer merits direct risk assessment regardless of total. Further errors include scoring reverse-coded items incorrectly, applying an unvalidated language translation, using the maternal cutoff for every father or partner, and comparing EPDS with PHQ-9 numbers as though both were on the same scale.
A particularly dangerous error is attempting to rule out postpartum psychosis through EPDS. Acute psychosis requires immediate professional attention even if the person endorses little sadness. Finally, a screening service can commit an organizational error by collecting answers without ensuring clinical review and a pathway to care. A technically correct score without a responsible response may still leave a vulnerable person unsupported.
Practical guidance for patients and families
When completing EPDS, choose the response that best represents the past week rather than the response you think a clinician wants. If a question feels unclear or does not fit your circumstances, ask for assistance rather than guessing; if you fear consequences of disclosure, ask how the service handles privacy, safeguarding and emergencies. Tell the clinician about concerns that the questionnaire does not address, including intrusive thoughts, panic, overwhelming worry, prolonged insomnia, unexpectedly elevated energy, frightening beliefs, or feeling unsafe.
If you receive a concerning score, ask what threshold your clinic uses, how soon a clinician will review the answers, whether further diagnostic assessment is arranged, and whom to contact if symptoms worsen. If a clinician concludes that depression is not present, you may still benefit from help with anxiety, trauma, sleep, pain, relationship stress, loss or practical pressures. Screening is one entry point into a broader assessment of your needs.
Partners and family members can encourage someone to discuss their symptoms and offer logistical support with appointments, rest, childcare and transportation. The person experiencing distress should remain central to decisions about disclosure and treatment except where emergency safety responsibilities apply. When acute risk signs are present, timely professional action takes priority over interpreting a questionnaire score.
Frequently asked questions
Is an EPDS score of 10 positive?
A score of 10 meets the ≥10 threshold used in some protocols and studies, but interpretation depends on the clinic's chosen cutoff and the person's circumstances. Research shows that ≥10 has higher sensitivity and lower specificity than ≥13. It is a prompt for context-sensitive follow-up rather than a diagnosis (Levis et al., 2020).
Is an EPDS score of 13 a diagnosis of postpartum depression?
No. A cutoff of ≥13 is relatively specific in pooled studies, but its sensitivity is lower, and a screening score alone does not satisfy diagnostic criteria. Further clinical evaluation determines the condition and appropriate care (Levis et al., 2020).
Can someone have postpartum depression with a low EPDS score?
Yes. No screening threshold detects every true case. Symptoms may fluctuate, be concealed, be interpreted differently across languages, or fall outside the questionnaire's week of recall. Persistent concerns and impairment justify assessment even after a low score.
Does the EPDS diagnose postpartum anxiety?
No. Anxiety-related items contribute to the total, and an EPDS anxiety subset has been studied, but the diagnosis of an anxiety disorder requires a separate clinical assessment. A dedicated anxiety screening tool can be used when appropriate (ACOG patient screening; PLOS ONE, 2019).
What if the self-harm question is positive but the total is low?
Clinicians should promptly assess the nature and immediacy of the thoughts regardless of the total. If there is immediate danger, seek emergency help. A low depression-screening score never overrides a direct safety concern (ACOG patient screening).
Can the EPDS be used while pregnant?
Yes. It has been evaluated in pregnancy as well as postpartum, and major professional guidelines include validated perinatal depression screening at antenatal visits. Screening should connect to assessment and treatment pathways (Levis et al., 2020; ACOG, 2023).
Should EPDS be completed online without a clinician?
An online form can prompt someone to seek care, but it cannot independently diagnose depression or evaluate immediate safety. A digital implementation should use the validated items and scoring, protect privacy, address concerning self-harm responses and provide an accessible follow-up route. Personal interpretation of a score must remain provisional.
Can clinicians use the same cutoff for fathers?
Evidence from paternal samples suggests that some lower cutoffs may be useful, but study size and heterogeneity constrain generalization. Clinicians should rely on validation and local protocols appropriate to fathers or non-birthing parents, alongside full assessment (Shafian et al., 2022).
Synthesis: what the score can and cannot decide
EPDS offers a practical, research-supported way to open a clinical discussion about depressive symptoms during pregnancy and postpartum. Its ten items and seven-day recall are efficient; its score is a starting signal interpreted against diagnostic evidence, functioning, history, individual circumstances, and safety. The strongest pooled research supports ≥11 as the threshold balancing sensitivity and specificity for major-depression screening, while ≥10 and ≥13 illustrate different clinical tradeoffs. A self-harm response demands separate follow-up, and suspected psychosis or mania demands urgent direct assessment regardless of the numeric result.
The scientific value of the EPDS is realized when clinicians preserve the distinction between measurement, diagnosis, and care. A well-supported perinatal mental health system provides validated administration, interprets scores in context, responds safely to warning signs and ensures that screened individuals can reach appropriate help. Those principles make the instrument clinically meaningful within the broader research field of Cluster Perinatal and Reproductive Mental Health.
Related Articles
Baby Blues vs Postpartum Depression: Symptoms, Duration, and Help — a clinical comparison of transient postpartum adjustment, depressive symptoms, and the role of screening instruments within diagnostic assessment.
Cluster Perinatal and Reproductive Mental Health — the published central scientific chapter covering the clinical, reproductive and healthcare contexts of perinatal mental health.
Perinatal OCD: What Is It? OCD During Pregnancy and Postpartum—Symptoms, Risk, and Treatment — research on perinatal obsessive-compulsive presentations that require evaluation beyond depression screening.
Postpartum OCD: What Is It? Intrusive Thoughts, Compulsions, Diagnosis, and Treatment After Childbirth — clinical differentiation of unwanted intrusive thoughts, compulsions, and postpartum psychiatric risk.
Eating Disorders During Pregnancy and Postpartum: Care and Risks — assessment of a related reproductive-period mental health condition outside the EPDS's specific screening remit.
References
American College of Obstetricians and Gynecologists (ACOG). (2023). Screening and diagnosis of mental health conditions during pregnancy and postpartum. Clinical Practice Guideline No. 4. Official guideline.
American College of Obstetricians and Gynecologists (ACOG). (2023). Treatment and management of mental health conditions during pregnancy and postpartum. Clinical Practice Guideline No. 5. Official guideline.
American College of Obstetricians and Gynecologists (ACOG). (n.d.). Implementing perinatal mental health screening. Official clinical toolkit.
American College of Obstetricians and Gynecologists (ACOG). (n.d.). Patient screening. Official perinatal mental health guidance.
Austin, M.-P. V., et al. (2022). Screening for anxiety disorders in third trimester pregnancy: A comparison of four brief measures. Archives of Women's Mental Health, 25, 389–397. DOI: 10.1007/s00737-021-01166-9.
Cox, J. L., Holden, J. M., & Sagovsky, R. (1987). Detection of postnatal depression: Development of the 10-item Edinburgh Postnatal Depression Scale. British Journal of Psychiatry, 150, 782–786. DOI: 10.1192/bjp.150.6.782.
Healthcare Improvement Scotland. (n.d.). Questionnaires and scoring tools: Mental health in pregnancy and after birth (SIGN 169). Official guidance and EPDS versions.
Hewitt, C. E., et al. (2009). Is it clinically and cost effective to screen for postnatal depression? A systematic review of controlled clinical trials and economic evidence. BJOG. PubMed PMID: 19438499.
Levis, B., et al. (2020). Accuracy of the Edinburgh Postnatal Depression Scale (EPDS) for screening to detect major depression among pregnant and postpartum women: Systematic review and meta-analysis of individual participant data. BMJ, 371, m4022. DOI: 10.1136/bmj.m4022.
National Institute for Health and Care Excellence (NICE). (2014, updated). Antenatal and postnatal mental health: Clinical management and service guidance (CG192). Official recommendations.
PLOS ONE. (2019). The Edinburgh Postpartum Depression Scale: Stable structure but subscale of limited value to detect anxiety. PLOS ONE, 14, e0221894. DOI: 10.1371/journal.pone.0221894.
Shafian, A. K., Mohamed, S., Raduan, N. J. N., & Ann, A. Y. H. (2022). A systematic review and meta-analysis of studies validating Edinburgh Postnatal Depression Scale in fathers. Heliyon, 8, e09441. DOI: 10.1016/j.heliyon.2022.e09441.
Selective cutoff reporting in studies of the accuracy of the Patient Health Questionnaire-9 and Edinburgh Postnatal Depression Scale: Comparison of results based on published cutoffs versus all cutoffs using individual participant data meta-analysis. (2021). International Journal of Methods in Psychiatric Research. PubMed PMID: 33978306.
U.S. Preventive Services Task Force (USPSTF). (2023). Depression and suicide risk in adults: Screening. Official recommendation.